Mar 07,2022

Real-World Use of Continuous Glucose Monitoring (CGM) Systems Among Adolescents and Young Adults With Type 1 Diabetes: Reduced Burden, but Little Interest in Data Analysis

Since 2016, German health insurance companies reimburse continuous glucose monitoring (CGM) systems for persons with insulin-dependent diabetes, leading to a tremendous increase of CGM use. This study assessed the use of CGM, the satisfaction with, and the data analysis behavior among young people.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Mar 08,2022

LifeScan is Proud to be a Founding Supporter of The Diabetes Way Website

LifeScan, a world leader in blood glucose monitoring and digital health technology, is committed to supporting resources that help promote diabetes education and improved health management, including their most recent sponsorship of The Diabetes Way website, offering a straight-forward educational resource.

View Analyst & Ambassador Comments
Go to original news
Mar 08,2022

Tandem Diabetes warns on some t:slim X2 insulin pumps

Tandem Diabetes Care (Nasdaq:TNDM) issued an urgent field safety notice in Europe for its t:slim X2 insulin pump with Basal-IQ technology. The notice, dated February 2022, alerts users of Tandem’s insulin pump with a software version of 6.3.0.1 that there may be a potential safety risk when using the pump within its normal specifications.

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Mar 09,2022

DarioHealth Announces Two New Contracts within the Employer and Provider Market

DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today new agreements with a regional employer and a regional provider. The contracts are expected to launch in the second quarter of 2022.

View Analyst & Ambassador Comments
Go to original news
Mar 09,2022

Vida Health Launches the Most Comprehensive Virtual Care Solution for Small Businesses

Vida for Small Business will provide the same 1:1 personalized care that’s available to large Vida clients like PayPal, Boeing, and Prudential.

PRODUCT

#virtual care

View Analyst & Ambassador Comments
Go to original news
Mar 09,2022

Global Insulin Patch Pumps Market Research Report 2022: Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2019-2029

Market size and forecast for these regional and country level markets are presented in this study for the period 2019-2029. Market growth rates for the forecast period 2019-2029 are also included in this report, considering 2020 as the base year.

View Analyst & Ambassador Comments
Go to original news
Mar 09,2022

Welldoc Named to AVIA Connect’s Top 50 Companies in Remote Monitoring Report

Welldoc®, a digital health leader revolutionizing chronic care, today announced that it was recognized as a Top 50 Company in remote monitoring upon conclusion of extensive research and company outreach by AVIA Connect, the leading digital health marketplace.

View Analyst & Ambassador Comments
Go to original news
Mar 14,2022

DarioHealth to Report Fourth Quarter and Full Year 2021 Results on Monday, March 21

DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, today announced it would release its financial results for the fourth quarter and full year ended December 31, 2021 on Monday, March 21, 2022, after the close of trading. The company will host a conference call and webcast on Tuesday, March 22, at 8:30 am Eastern Time.

View Analyst & Ambassador Comments
Go to original news
Mar 14,2022

Medtronic announces recent reimbursement wins for CGMs in a number of geographies

Medtronic plc, a global leader in healthcare technology, today announced that reimbursement for continuous glucose monitoring (CGM), a key diabetes technology has been recently expanded or initiated in several countries throughout North and South America.

PRODUCT

#cgm

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Mar 14,2022

Development and Validation of the Diabetes Pen Experience Measure (DPEM): A New Patient-Reported Outcome Measure

The Diabetes Pen Experience Measure (DPEM) is a new patient-reported outcome measure to evaluate patients’ experience when using an injection device.

CLINICAL STUDY

#insulin pen

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES